Prelude Corp. announced that Clinical Cancer Research published results from a large cross-validation study of DCISionRT in patients with ductal carcinoma in situ (Bremer T, et al. Epub ahead of print July 27, 2018. doi:10.1158/1078-0432.CCR-18-0842). The multisite study demonstrated that DCISionRT was a strong predictor of radiation benefit and was able to identify patients with significantly elevated recurrence risk that would be considered low risk by traditional clinical assessment.
“The study analyzed the biology and clinical factors of 526 patients using DCISionRT and demonstrated that the biologic signature was excellent at identifying which patients would have a DCIS or invasive breast cancer recurrence within 10 years,” lead investigator Fredrik Wärnberg, MD, PhD, associate professor of surgery, Uppsala University, and member of the Swedish Breast Cancer Group, said in a press release. It also distinguished the patients most likely to have clinically meaningful radiation therapy benefit from patients who would not.
“This is in contrast to previous studies that consistently showed a 50 percent risk reduction for all patients receiving radiation therapy, whereas the DCISionRT Score identified a group of patients that had nearly twice the risk reduction typically expected (risk reduction of 70 percent or more),” the company reports.